Home › Funds › PSP Research LLC › ELVN

PSP Research LLC position in ELVN

ENLIVEX THERAPEUTICS LTD · Health Care

PSP Research LLC reported holding 7,000 shares of ELVN (ENLIVEX THERAPEUTICS LTD) in its Q2 2026 13F filing — a position valued at US$355K, representing 0.19% of its reported portfolio and ranking #41 among its reported holdings. PSP Research LLC has disclosed ELVN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)7.00K sh
Reported value held$355.25K
Portfolio Weight0.19%
First reportedQ1 2026
Last changeNew

How PSP Research LLC's ELVN position evolved

PSP Research LLC first disclosed a stake in ELVN in Q1 2026 at 7,000 shares (US$274K). The position peaked in Q2 2026 at 7,000 shares, worth US$355K. Across 2 filings, PSP Research LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 7,000 shares valued at US$355K.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 7.00K $274.40K New
Q2 2026 7.00K $355.25K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEX THERAPEUTICS LTD) is a Health Care company. 68 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →